## Contents

Preface ................................................................. vii  
Contributors ......................................................... xi  
1 Defining the Problem: From Subclinical Disease to Clinically Insignificant Prostate Cancer ................................. 1  
   Wael Sakr  
2 What Every Patient Should Know about Prostate Cancer Before He Submits to Biopsy of His Prostate ...................... 13  
   Thomas A. Stamey, Rosalie Nolley, and Dorothea Torti  
3 Prostate-Specific Antigen and Prostate Cancer Screening .......... 15  
   Stacy Loeb, Misop Han, and William J. Catalona  
4 The Role of Complexed Prostate-Specific Antigen in Prostate Cancer Screening ............................................. 29  
   Matthew E. Nielsen and Alan W. Partin  
5 Newly Recognized Forms of Prostate-Specific Antigen and Emerging Molecular Markers .................................. 43  
   Eduardo I. Canto and Kevin M. Slawin  
6 The Role of Prostate-Specific Antigen Velocity in the Diagnosis and Management of Prostate Cancer .................. 61  
   H. Ballentine Carter  
7 Prostate Cancer Screening: Navigating the Controversy .......... 71  
   Timothy C. Brand and Ian M. Thompson  
8 Prostate Cancer Nomograms and How They Measure Up to Neural Networks .................................................. 83  
   Pierre I. Karakiewicz and Michael W. Kattan  
9 Preparation for Prostate Biopsy .................................... 97  
   Alan M. Nieder and Mark S. Soloway  
10 Principles of Prostate Ultrasound .................................. 105  
   Martha K. Terris  
11 Minimizing Pain and Optimizing Patient Experience During Prostate Biopsy ................................................. 121  
   J. Stephen Jones  
12 Prostate Biopsy Techniques ........................................ 143  
   Katsuto Shinohara  
13 Biopsy Strategies—How Many and Where? ....................... 165  
   Joseph C. Presti, Jr.
<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Authors</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>14</td>
<td>Transperineal Prostate Biopsy</td>
<td>Paolo Emiliozzi and Vito Pansadoro</td>
<td>179</td>
</tr>
<tr>
<td>15</td>
<td>Repeat Prostate Biopsies and the Vienna Nomograms.</td>
<td>Bob Djavan and Sibylle Marthart</td>
<td>199</td>
</tr>
<tr>
<td>16</td>
<td>Saturation Biopsy for Detection and Characterization of Prostate Cancer</td>
<td>J. Stephen Jones</td>
<td>217</td>
</tr>
<tr>
<td>17</td>
<td>Pathologic Implications of Prostate Biopsy</td>
<td>Ming Zhou and Cristina Magi-Galluzzi</td>
<td>231</td>
</tr>
<tr>
<td>18</td>
<td>Complications of Transrectal Ultrasound–Guided Prostate Biopsy</td>
<td>Sam S. Chang and Michael S. Cookson</td>
<td>255</td>
</tr>
<tr>
<td>19</td>
<td>Management and Controversies of High-Grade Prostatic Intraepithelial Neoplasia and Atypical Small Acinar Proliferation on Prostate Biopsy</td>
<td>Alon Z. Weizer, Scott M. Gilbert, Rajal B. Shah, and David P. Wood, Jr.</td>
<td>269</td>
</tr>
<tr>
<td>20</td>
<td>Future Directions in Prostate Cancer Diagnosis</td>
<td>Nicholas J. Fitzsimons, Lionel L. Bañez, Leon L. Sun, and Judd W. Moul</td>
<td>287</td>
</tr>
</tbody>
</table>

Index                                                                 | 313